ArticleInternational journal of women's dermatology2026
Characterizing cutaneous manifestations of systemic autoimmune rheumatologic diseases in Filipino skin.
Article in International journal of women's dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous findings provide important clues to systemic autoimmune rheumatologic diseases (SARDs), but presentation varies across skin types and may be underrecognized in patients of color. In the Philippines, diagnostic challenges are amplified by limited specialists and a lack of pigmented-skin learning materials for general practitioners. Objective: To develop online educational resources on cutaneous manifestations of SARDs in Filipino skin (phases 1 and 2a), and characterize the demographic and clinical profile of these patients (phase 2b). Methods: Phase 1 videos were created and posted online for sharing. Phase 2 was a single-center cross-sectional descriptive study that included consenting adult Filipinos at least 18 years old who presented with the above-mentioned SARDs and skin lesions in the Philippine General Hospital's Dermatology and Rheumatology outpatient clinics from August 2021 to August 2022. Demographic, medical data, and deidentified photographic images of characteristic lesions were captured. Investigators described the observed differences in the skin disease presentation of Filipino skin. Descriptive statistics were applied. Results: Forty-six Filipinos, 85% being female, with a mean age of 39.1 years, participated in our study. The majority (48%) had a primary diagnosis of systemic lupus erythematosus, followed by psoriasis (26%). Most (96.6%) were on immunomodulators and 57% on glucocorticoids. Three (7%) were on biologic medications. Notable differences of lesions between Filipino and Caucasian skin include the former being: (a) dark red, purple or dark brown instead of pink and bright erythema; (b) masked by pigmentation or the "blending" phenomenon; (c) more marked in contrast between hyper- and hypopigmentation; (d) more gray and black psoriatic plaques; resembling purpuric dermatoses; and (e) with blurring of skin tautness and edema in those with systemic sclerosis. There are no significant differences observed in the areas of affectation. Limitations: Phase 2 was limited by the pandemic and methodological constraints, highlighting the need for further research on cutaneous manifestations of rheumatologic diseases in Filipinos. Conclusion: There are differences in lesion morphology, pigmentation, and scarring, but not in areas of affectation, in the darker skin of Filipinos with SARD. Collaboration between dermatologists and rheumatologists is essential for the effective management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.